Lead Product(s) : Fluocytosine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides receives USFDA Approval for Flucytosine Capsules
Details : USFDA approved generic version of Flucytosine Capsule (thymidylate synthetase inhibitor) indicated for treating serious infections caused by susceptible strains of Candida and/or Cryptococcus (meningitis and pulmonary infections)
Product Name : Ancobon-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 20, 2020
Lead Product(s) : Fluocytosine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluocytosine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Pharma Gets USFDA Nod For Flucytosine Capsules
Details : Flucytosine capsules are generic version of Bausch Health's Ancobon capsules. The product will be launched in June 2020.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2020
Lead Product(s) : Fluocytosine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
